Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

MIF molecule plays crucial role in neurogenesis

There has been little progress in the way we treat depression and anxiety for over thirty years, but a recent study at EPFL Ecole Polytechnique Fédérale de Lausanne (EPFL) may open the door to new strategies. In an article published online February 23, 2010, in Molecular Psychiatry, researchers from two laboratories at the Brain Mind Institute at EPFL (Ecole Polytechnique Fédérale de Lausanne) explain how understanding the functioning of a molecule called MIF, or macrophage migration inhibitory factor, may change the way we treat depression.

12 Apr 2010

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.

12 Apr 2010

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Scientists at The University of Western Ontario have discovered the biological link between stress, anxiety and depression. By identifying the connecting mechanism in the brain, this high impact research led by Stephen Ferguson of Robarts Research Institute shows exactly how stress and anxiety could lead to depression.

12 Apr 2010

Dealing with emotional impacts of bullying before it's too late

The California Association of Marriage and Family Therapists (CAMFT) encourages parents to talk with teens about bullying before it's too late. A conversation can be an important first step in identifying a bullying problem and stopping the abuse before it goes too far.

8 Apr 2010

Transcendental Meditation may reduce symptoms of depression

The Transcendental Meditation- technique may be an effective approach to reduce symptoms of depression, according to two new studies to be presented at the 31st Annual Meeting of the Society of Behavioral Medicine in Seattle, Washington April 9th, 2010.

8 Apr 2010

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

8 Apr 2010

Study: Genetic mutation in mice elevates risk of stress-induced depression

Depression and schizophrenia can be triggered by environmental stimuli and often occur in response to stressful life events. However, some people have a higher predisposition to develop these diseases, which highlights a role for genetics in determining a person's disease risk.

6 Apr 2010

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

Alaska Northern Lights manufactures a bright light therapy box that aids in treating chronic health problems such as seasonal affective disorder (SAD), depression, bipolar disorder and sleep problems. Sufferers of SAD, a form of clinical depression, include up to 25 percent of those living in northern latitudes who experience varying degrees of SAD during winter months when there is less natural light. Night shift workers are also susceptible to SAD which affects over one third of the population, or about 10.8 million Americans.

31 Mar 2010

PMDD often misdiagnosed as major depression or other mood disorder

As science slowly, but continually, unravels the causes of disorders, it increasingly teases apart biological threads that, when spooled together, begin to take on the warp and weft of separate disorders.

31 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

The next advance in treating major depression may relate to a group of brain chemicals that are involved in virtually all our brain activity, according to a study published today in Biological Psychiatry.

2 Mar 2010

Study challenges psychiatrists' official diagnostic manual in preventing mistaken diagnoses of depression

A study in the March edition of the American Journal of Psychiatry senior-authored by Jerome C. Wakefield, a professor at the Silver School of Social Work at New York University with Mark Schmitz of Temple University and Judith Baer of Rutgers University, empirically challenges the effectiveness of psychiatrists' official diagnostic manual in preventing mistaken, false-positive diagnoses of depression.

25 Feb 2010

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia.

25 Feb 2010

Religious belief can reduce depression symptoms

Research suggests that religious belief can help protect against symptoms of depression, but a study at Rush University Medical Center goes one step further.

24 Feb 2010

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.

23 Feb 2010

Study shows prevalence of depression among low-income urban mothers

More than half of low-income urban mothers met the criteria for a diagnosis of depression at some point between two weeks and 14 months after giving birth, according to a study led by University of Rochester Medical Center researchers and published online by the journal Pediatrics.

19 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Women with low levels of income are susceptible to anxiety and depression after diagnosed with DCIS

A new analysis has found that women with medium or low levels of income are particularly susceptible to anxiety and depression after being diagnosed with the precancerous breast condition, ductal carcinoma in situ (DCIS).

8 Feb 2010

Major Depressive Disorder News and Research

Further Reading

MIF molecule plays crucial role in neurogenesis

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Dealing with emotional impacts of bullying before it's too late

Transcendental Meditation may reduce symptoms of depression

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Study: Genetic mutation in mice elevates risk of stress-induced depression

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

PMDD often misdiagnosed as major depression or other mood disorder

Clinical Data completes NDA submission for vilazodone

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Moderating treatment response in depression: Role of personality factors

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

Study challenges psychiatrists' official diagnostic manual in preventing mistaken diagnoses of depression

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Religious belief can reduce depression symptoms

Watson Laboratories files ANDA for generic Aplenzin ER in treatment of major depressive disorder

Study shows prevalence of depression among low-income urban mothers

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Women with low levels of income are susceptible to anxiety and depression after diagnosed with DCIS

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News